| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | metalloendopeptidase activity | 4.50e-09 | 120 | 41 | 7 | GO:0004222 | |
| GeneOntologyMolecularFunction | metallopeptidase activity | 1.53e-07 | 200 | 41 | 7 | GO:0008237 | |
| GeneOntologyMolecularFunction | endopeptidase activity | 2.44e-05 | 430 | 41 | 7 | GO:0004175 | |
| GeneOntologyMolecularFunction | proteoglycan binding | 1.56e-04 | 51 | 41 | 3 | GO:0043394 | |
| GeneOntologyMolecularFunction | peptidase activity | 3.34e-04 | 654 | 41 | 7 | GO:0008233 | |
| GeneOntologyMolecularFunction | sialic acid binding | 1.20e-03 | 25 | 41 | 2 | GO:0033691 | |
| GeneOntologyMolecularFunction | metalloaminopeptidase activity | 1.30e-03 | 26 | 41 | 2 | GO:0070006 | |
| GeneOntologyMolecularFunction | scavenger receptor activity | 1.40e-03 | 27 | 41 | 2 | GO:0005044 | |
| GeneOntologyMolecularFunction | polysaccharide binding | 1.84e-03 | 31 | 41 | 2 | GO:0030247 | |
| GeneOntologyMolecularFunction | zinc ion binding | 2.05e-03 | 891 | 41 | 7 | GO:0008270 | |
| GeneOntologyMolecularFunction | P-type transmembrane transporter activity | 2.48e-03 | 36 | 41 | 2 | GO:0140358 | |
| GeneOntologyMolecularFunction | P-type ion transporter activity | 2.48e-03 | 36 | 41 | 2 | GO:0015662 | |
| GeneOntologyMolecularFunction | aminopeptidase activity | 3.52e-03 | 43 | 41 | 2 | GO:0004177 | |
| GeneOntologyMolecularFunction | carbohydrate binding | 3.67e-03 | 310 | 41 | 4 | GO:0030246 | |
| GeneOntologyMolecularFunction | sulfur compound binding | 4.25e-03 | 323 | 41 | 4 | GO:1901681 | |
| GeneOntologyBiologicalProcess | extracellular matrix organization | MMP25 LRP1 ADAMTS10 COL5A3 VTN MMP2 MMP11 MMP16 MMP17 MMP19 ANGPTL7 | 1.27e-10 | 377 | 41 | 11 | GO:0030198 |
| GeneOntologyBiologicalProcess | extracellular structure organization | MMP25 LRP1 ADAMTS10 COL5A3 VTN MMP2 MMP11 MMP16 MMP17 MMP19 ANGPTL7 | 1.31e-10 | 378 | 41 | 11 | GO:0043062 |
| GeneOntologyBiologicalProcess | external encapsulating structure organization | MMP25 LRP1 ADAMTS10 COL5A3 VTN MMP2 MMP11 MMP16 MMP17 MMP19 ANGPTL7 | 1.35e-10 | 379 | 41 | 11 | GO:0045229 |
| GeneOntologyBiologicalProcess | collagen catabolic process | 9.02e-10 | 53 | 41 | 6 | GO:0030574 | |
| GeneOntologyBiologicalProcess | collagen metabolic process | 4.51e-07 | 148 | 41 | 6 | GO:0032963 | |
| GeneOntologyBiologicalProcess | extracellular matrix disassembly | 1.47e-05 | 75 | 41 | 4 | GO:0022617 | |
| GeneOntologyBiologicalProcess | positive regulation of ATPase-coupled calcium transmembrane transporter activity | 5.75e-05 | 6 | 41 | 2 | GO:1901896 | |
| GeneOntologyCellularComponent | extracellular matrix | MMP25 ADAMTS10 COL5A3 ANGPTL6 VTN MMP2 MMP11 MMP16 MMP17 MMP19 ANGPTL7 FCN2 WNT2 | 2.00e-10 | 656 | 41 | 13 | GO:0031012 |
| GeneOntologyCellularComponent | external encapsulating structure | MMP25 ADAMTS10 COL5A3 ANGPTL6 VTN MMP2 MMP11 MMP16 MMP17 MMP19 ANGPTL7 FCN2 WNT2 | 2.07e-10 | 658 | 41 | 13 | GO:0030312 |
| GeneOntologyCellularComponent | side of membrane | 5.39e-06 | 875 | 41 | 10 | GO:0098552 | |
| GeneOntologyCellularComponent | collagen-containing extracellular matrix | 7.41e-06 | 530 | 41 | 8 | GO:0062023 | |
| GeneOntologyCellularComponent | sarcoglycan complex | 5.60e-05 | 6 | 41 | 2 | GO:0016012 | |
| GeneOntologyCellularComponent | dystroglycan complex | 7.83e-05 | 7 | 41 | 2 | GO:0016011 | |
| GeneOntologyCellularComponent | external side of plasma membrane | 4.89e-04 | 519 | 41 | 6 | GO:0009897 | |
| GeneOntologyCellularComponent | sarcoplasmic reticulum | 6.85e-04 | 88 | 41 | 3 | GO:0016529 | |
| GeneOntologyCellularComponent | dystrophin-associated glycoprotein complex | 6.97e-04 | 20 | 41 | 2 | GO:0016010 | |
| GeneOntologyCellularComponent | glycoprotein complex | 1.09e-03 | 25 | 41 | 2 | GO:0090665 | |
| GeneOntologyCellularComponent | cell surface | 1.24e-03 | 1111 | 41 | 8 | GO:0009986 | |
| GeneOntologyCellularComponent | Golgi lumen | 1.27e-03 | 109 | 41 | 3 | GO:0005796 | |
| GeneOntologyCellularComponent | sarcoplasm | 1.45e-03 | 114 | 41 | 3 | GO:0016528 | |
| GeneOntologyCellularComponent | sarcoplasmic reticulum membrane | 3.52e-03 | 45 | 41 | 2 | GO:0033017 | |
| Domain | Hemopexin-like_dom | 2.34e-14 | 23 | 39 | 7 | IPR000585 | |
| Domain | Hemopexin | 2.34e-14 | 23 | 39 | 7 | PF00045 | |
| Domain | HEMOPEXIN | 2.34e-14 | 23 | 39 | 7 | PS00024 | |
| Domain | - | 2.34e-14 | 23 | 39 | 7 | 2.110.10.10 | |
| Domain | HEMOPEXIN_2 | 2.34e-14 | 23 | 39 | 7 | PS51642 | |
| Domain | Hemopexin-like_repeat | 2.34e-14 | 23 | 39 | 7 | IPR018487 | |
| Domain | HX | 2.34e-14 | 23 | 39 | 7 | SM00120 | |
| Domain | Pept_M10A | 5.45e-12 | 23 | 39 | 6 | IPR021190 | |
| Domain | M10A_MMP | 5.45e-12 | 23 | 39 | 6 | IPR033739 | |
| Domain | Peptidase_M10 | 7.25e-12 | 24 | 39 | 6 | PF00413 | |
| Domain | ZnMc | 2.54e-11 | 29 | 39 | 6 | SM00235 | |
| Domain | Peptidase_Metallo | 2.54e-11 | 29 | 39 | 6 | IPR006026 | |
| Domain | CYSTEINE_SWITCH | 2.36e-10 | 41 | 39 | 6 | PS00546 | |
| Domain | Pept_M10A_stromelysin-type | 2.56e-10 | 18 | 39 | 5 | IPR016293 | |
| Domain | MetalloPept_cat_dom | 3.05e-10 | 81 | 39 | 7 | IPR024079 | |
| Domain | - | 3.05e-10 | 81 | 39 | 7 | 3.40.390.10 | |
| Domain | Pept_M10_metallopeptidase | 3.19e-10 | 43 | 39 | 6 | IPR001818 | |
| Domain | PG_binding_1 | 4.61e-10 | 20 | 39 | 5 | PF01471 | |
| Domain | Peptidoglycan-bd-like | 4.61e-10 | 20 | 39 | 5 | IPR002477 | |
| Domain | ZINC_PROTEASE | 1.18e-09 | 98 | 39 | 7 | PS00142 | |
| Domain | Hemopexin_CS | 3.79e-08 | 17 | 39 | 4 | IPR018486 | |
| Domain | Pept_M10A_Zn_BS | 3.76e-06 | 15 | 39 | 3 | IPR021158 | |
| Domain | - | 1.65e-05 | 24 | 39 | 3 | 4.10.530.10 | |
| Domain | Fibrinogen_a/b/g_C_2 | 1.65e-05 | 24 | 39 | 3 | IPR014715 | |
| Domain | Fibrinogen_C | 2.38e-05 | 27 | 39 | 3 | PF00147 | |
| Domain | Sarcoglycan_1 | 2.54e-05 | 4 | 39 | 2 | PF04790 | |
| Domain | - | 2.54e-05 | 4 | 39 | 2 | 1.10.101.10 | |
| Domain | Sarcoglycan | 2.54e-05 | 4 | 39 | 2 | IPR006875 | |
| Domain | FBG | 2.96e-05 | 29 | 39 | 3 | SM00186 | |
| Domain | - | 3.29e-05 | 30 | 39 | 3 | 3.90.215.10 | |
| Domain | Fibrinogen_a/b/g_C_1 | 3.29e-05 | 30 | 39 | 3 | IPR014716 | |
| Domain | Fibrinogen_a/b/g_C_dom | 4.00e-05 | 32 | 39 | 3 | IPR002181 | |
| Domain | FIBRINOGEN_C_2 | 4.00e-05 | 32 | 39 | 3 | PS51406 | |
| Domain | FIBRINOGEN_C_1 | 4.00e-05 | 32 | 39 | 3 | PS00514 | |
| Domain | Methyltransf_11 | 5.01e-04 | 16 | 39 | 2 | PF08241 | |
| Domain | Methyltransf_11 | 5.01e-04 | 16 | 39 | 2 | IPR013216 | |
| Domain | Cation_ATPase_N | 6.36e-04 | 18 | 39 | 2 | PF00690 | |
| Domain | Cation_ATPase_N | 6.36e-04 | 18 | 39 | 2 | SM00831 | |
| Domain | ATPase_P-typ_cation-transptr_N | 7.10e-04 | 19 | 39 | 2 | IPR004014 | |
| Domain | Fibrinogen_CS | 7.10e-04 | 19 | 39 | 2 | IPR020837 | |
| Domain | - | 2.03e-03 | 32 | 39 | 2 | 2.70.150.10 | |
| Domain | - | 2.03e-03 | 32 | 39 | 2 | 3.40.1110.10 | |
| Domain | ATPase_P-typ_cyto_domN | 2.42e-03 | 35 | 39 | 2 | IPR023299 | |
| Domain | ATPase_P-typ_P_site | 2.56e-03 | 36 | 39 | 2 | IPR018303 | |
| Domain | P_typ_ATPase | 2.56e-03 | 36 | 39 | 2 | IPR001757 | |
| Domain | ATPASE_E1_E2 | 2.56e-03 | 36 | 39 | 2 | PS00154 | |
| Domain | ATPase_P-typ_transduc_dom_A | 2.70e-03 | 37 | 39 | 2 | IPR008250 | |
| Domain | E1-E2_ATPase | 2.70e-03 | 37 | 39 | 2 | PF00122 | |
| Domain | HAD-like_dom | 1.18e-02 | 79 | 39 | 2 | IPR023214 | |
| Pathway | WP_MATRIX_METALLOPROTEINASES | 1.59e-11 | 29 | 28 | 6 | MM15981 | |
| Pathway | WP_MATRIX_METALLOPROTEINASES | 1.99e-11 | 30 | 28 | 6 | M39652 | |
| Pathway | WP_CHRONIC_HYPERGLYCEMIA_IMPAIRMENT_OF_NEURON_FUNCTION | 3.07e-10 | 46 | 28 | 6 | M46450 | |
| Pathway | REACTOME_DEGRADATION_OF_THE_EXTRACELLULAR_MATRIX | 1.93e-09 | 114 | 28 | 7 | MM14571 | |
| Pathway | REACTOME_ACTIVATION_OF_MATRIX_METALLOPROTEINASES | 4.84e-09 | 33 | 28 | 5 | M26976 | |
| Pathway | REACTOME_DEGRADATION_OF_THE_EXTRACELLULAR_MATRIX | 8.15e-09 | 140 | 28 | 7 | M587 | |
| Pathway | REACTOME_ACTIVATION_OF_MATRIX_METALLOPROTEINASES | 1.02e-08 | 38 | 28 | 5 | MM14611 | |
| Pathway | REACTOME_EXTRACELLULAR_MATRIX_ORGANIZATION | 2.56e-08 | 258 | 28 | 8 | MM14572 | |
| Pathway | REACTOME_EXTRACELLULAR_MATRIX_ORGANIZATION | 8.23e-08 | 300 | 28 | 8 | M610 | |
| Pathway | REACTOME_COLLAGEN_DEGRADATION | 7.29e-06 | 64 | 28 | 4 | M26953 | |
| Pathway | REACTOME_COLLAGEN_DEGRADATION | 1.54e-04 | 53 | 28 | 3 | MM14566 | |
| Pathway | WP_ARRHYTHMOGENIC_RIGHT_VENTRICULAR_CARDIOMYOPATHY | 4.14e-04 | 74 | 28 | 3 | M39462 | |
| Pathway | KEGG_ARRHYTHMOGENIC_RIGHT_VENTRICULAR_CARDIOMYOPATHY_ARVC | 4.14e-04 | 74 | 28 | 3 | M16376 | |
| Pathway | KEGG_HYPERTROPHIC_CARDIOMYOPATHY_HCM | 5.80e-04 | 83 | 28 | 3 | M8728 | |
| Pathway | KEGG_DILATED_CARDIOMYOPATHY | 7.34e-04 | 90 | 28 | 3 | M835 | |
| Pathway | WP_COMPLEMENT_SYSTEM | 8.86e-04 | 96 | 28 | 3 | M39581 | |
| Pathway | REACTOME_SYNDECAN_INTERACTIONS | 1.29e-03 | 27 | 28 | 2 | M27217 | |
| Pubmed | Functional interactions between matrix metalloproteinases and glycosaminoglycans. | 1.35e-13 | 22 | 41 | 6 | 23421805 | |
| Pubmed | 1.35e-13 | 22 | 41 | 6 | 10419448 | ||
| Pubmed | Membrane-type matrix metalloproteinases: Their functions and regulations. | 5.80e-11 | 7 | 41 | 4 | 25794647 | |
| Pubmed | 7.39e-11 | 24 | 41 | 5 | 15734845 | ||
| Pubmed | 6.49e-10 | 36 | 41 | 5 | 20587546 | ||
| Pubmed | 2.99e-09 | 16 | 41 | 4 | 10949577 | ||
| Pubmed | 3.03e-08 | 6 | 41 | 3 | 14645246 | ||
| Pubmed | 1.45e-07 | 730 | 41 | 9 | 34857952 | ||
| Pubmed | 2.49e-07 | 11 | 41 | 3 | 10949161 | ||
| Pubmed | 5.49e-07 | 14 | 41 | 3 | 25636537 | ||
| Pubmed | 8.42e-07 | 16 | 41 | 3 | 37701782 | ||
| Pubmed | 1.36e-06 | 2 | 41 | 2 | 16084087 | ||
| Pubmed | 1.36e-06 | 2 | 41 | 2 | 10551873 | ||
| Pubmed | 1.36e-06 | 2 | 41 | 2 | 11257478 | ||
| Pubmed | Elevated Plasma Levels of MT4-MMP and MT6-MMP; A New Observation in Patients with Thyroid Nodules. | 1.36e-06 | 2 | 41 | 2 | 38310435 | |
| Pubmed | 1.36e-06 | 2 | 41 | 2 | 17217338 | ||
| Pubmed | 1.36e-06 | 2 | 41 | 2 | 18208802 | ||
| Pubmed | 1.36e-06 | 2 | 41 | 2 | 14991064 | ||
| Pubmed | Results in treatment of early breast cancers and the level of selected metalloproteinases. | 1.36e-06 | 2 | 41 | 2 | 22286800 | |
| Pubmed | 1.36e-06 | 2 | 41 | 2 | 9508784 | ||
| Pubmed | Secondary coronary artery vasospasm promotes cardiomyopathy progression. | 1.36e-06 | 2 | 41 | 2 | 14982859 | |
| Pubmed | SMAD signaling drives heart and muscle dysfunction in a Drosophila model of muscular dystrophy. | 1.36e-06 | 2 | 41 | 2 | 21138941 | |
| Pubmed | 2.66e-06 | 186 | 41 | 5 | 20673868 | ||
| Pubmed | 2.66e-06 | 186 | 41 | 5 | 20452482 | ||
| Pubmed | 4.06e-06 | 3 | 41 | 2 | 17980449 | ||
| Pubmed | 4.06e-06 | 3 | 41 | 2 | 14583471 | ||
| Pubmed | 4.06e-06 | 3 | 41 | 2 | 18784838 | ||
| Pubmed | Functional nitric oxide synthase mislocalization in cardiomyopathy. | 4.06e-06 | 3 | 41 | 2 | 14871549 | |
| Pubmed | 4.06e-06 | 3 | 41 | 2 | 21665956 | ||
| Pubmed | 4.06e-06 | 3 | 41 | 2 | 18535179 | ||
| Pubmed | 4.06e-06 | 3 | 41 | 2 | 10862711 | ||
| Pubmed | 4.06e-06 | 3 | 41 | 2 | 24669030 | ||
| Pubmed | Mitigation of muscular dystrophy in mice by SERCA overexpression in skeletal muscle. | 4.06e-06 | 3 | 41 | 2 | 21285509 | |
| Pubmed | 4.06e-06 | 3 | 41 | 2 | 9417058 | ||
| Pubmed | Filamin 2 (FLN2): A muscle-specific sarcoglycan interacting protein. | 4.06e-06 | 3 | 41 | 2 | 10629222 | |
| Pubmed | 4.06e-06 | 3 | 41 | 2 | 11891989 | ||
| Pubmed | 4.06e-06 | 3 | 41 | 2 | 19176371 | ||
| Pubmed | 4.06e-06 | 3 | 41 | 2 | 24445321 | ||
| Pubmed | 6.04e-06 | 30 | 41 | 3 | 22171010 | ||
| Pubmed | 8.12e-06 | 4 | 41 | 2 | 8626514 | ||
| Pubmed | 8.12e-06 | 4 | 41 | 2 | 15895410 | ||
| Pubmed | 8.12e-06 | 4 | 41 | 2 | 8663332 | ||
| Pubmed | 8.12e-06 | 4 | 41 | 2 | 14506720 | ||
| Pubmed | Cleavage of β-dystroglycan occurs in sarcoglycan-deficient skeletal muscle without MMP-2 and MMP-9. | 8.12e-06 | 4 | 41 | 2 | 28821434 | |
| Pubmed | 8.12e-06 | 4 | 41 | 2 | 9384575 | ||
| Pubmed | 8.12e-06 | 4 | 41 | 2 | 10678176 | ||
| Pubmed | 8.12e-06 | 4 | 41 | 2 | 10942431 | ||
| Pubmed | 8.12e-06 | 4 | 41 | 2 | 24970228 | ||
| Pubmed | Developmental expression of sarcoglycan gene products in cultured myocytes. | 8.12e-06 | 4 | 41 | 2 | 10448073 | |
| Pubmed | 8.12e-06 | 4 | 41 | 2 | 25605665 | ||
| Pubmed | Sarcoglycanopathies: can muscle immunoanalysis predict the genotype? | 8.12e-06 | 4 | 41 | 2 | 18996010 | |
| Pubmed | 1.35e-05 | 5 | 41 | 2 | 12661033 | ||
| Pubmed | 1.35e-05 | 5 | 41 | 2 | 10993904 | ||
| Pubmed | 1.35e-05 | 5 | 41 | 2 | 18340378 | ||
| Pubmed | Molecular organization of sarcoglycan complex in mouse myotubes in culture. | 1.35e-05 | 5 | 41 | 2 | 9864373 | |
| Pubmed | RA Acts in a Coherent Feed-Forward Mechanism with Tbx5 to Control Limb Bud Induction and Initiation. | 1.35e-05 | 5 | 41 | 2 | 26212321 | |
| Pubmed | 1.35e-05 | 5 | 41 | 2 | 16524571 | ||
| Pubmed | Zeta-sarcoglycan, a novel component of the sarcoglycan complex, is reduced in muscular dystrophy. | 2.03e-05 | 6 | 41 | 2 | 12189167 | |
| Pubmed | 2.03e-05 | 6 | 41 | 2 | 21054788 | ||
| Pubmed | Matrix metalloproteinase activity in pediatric acute lung injury. | 2.03e-05 | 6 | 41 | 2 | 19159011 | |
| Pubmed | 2.03e-05 | 6 | 41 | 2 | 17181997 | ||
| Pubmed | 2.84e-05 | 7 | 41 | 2 | 26929074 | ||
| Pubmed | 2.84e-05 | 7 | 41 | 2 | 19542530 | ||
| Pubmed | Cleavage of metastasis suppressor gene product KiSS-1 protein/metastin by matrix metalloproteinases. | 2.84e-05 | 7 | 41 | 2 | 12879005 | |
| Pubmed | Sarcoglycan complex: implications for metabolic defects in muscular dystrophies. | 2.84e-05 | 7 | 41 | 2 | 19494113 | |
| Pubmed | Expression of matrix metalloproteinases during murine chorioallantoic placenta maturation. | 2.84e-05 | 7 | 41 | 2 | 10090151 | |
| Pubmed | 2.84e-05 | 7 | 41 | 2 | 22350948 | ||
| Pubmed | Common pathological mechanisms in mouse models for muscular dystrophies. | 2.84e-05 | 7 | 41 | 2 | 16306063 | |
| Pubmed | 2.84e-05 | 7 | 41 | 2 | 29547901 | ||
| Pubmed | 2.84e-05 | 7 | 41 | 2 | 10767327 | ||
| Pubmed | 3.78e-05 | 8 | 41 | 2 | 10488149 | ||
| Pubmed | Roles of IP3R and RyR Ca2+ channels in endoplasmic reticulum stress and beta-cell death. | 3.78e-05 | 8 | 41 | 2 | 19033399 | |
| Pubmed | 3.78e-05 | 8 | 41 | 2 | 17164264 | ||
| Pubmed | 3.78e-05 | 8 | 41 | 2 | 11784029 | ||
| Pubmed | 3.78e-05 | 8 | 41 | 2 | 8674412 | ||
| Pubmed | 3.78e-05 | 8 | 41 | 2 | 10481911 | ||
| Pubmed | 4.86e-05 | 9 | 41 | 2 | 9916808 | ||
| Pubmed | 4.86e-05 | 9 | 41 | 2 | 9108368 | ||
| Pubmed | 6.07e-05 | 10 | 41 | 2 | 18434328 | ||
| Pubmed | Genome-wide association analysis identifies susceptibility loci for migraine without aura. | 6.07e-05 | 10 | 41 | 2 | 22683712 | |
| Pubmed | 7.41e-05 | 11 | 41 | 2 | 36465133 | ||
| Pubmed | 7.41e-05 | 11 | 41 | 2 | 17903301 | ||
| Pubmed | Basement membrane remodelling regulates mouse embryogenesis. | 7.41e-05 | 11 | 41 | 2 | 32523119 | |
| Pubmed | Mouse model of muscleblind-like 1 overexpression: skeletal muscle effects and therapeutic promise. | 7.41e-05 | 11 | 41 | 2 | 22846424 | |
| Pubmed | 8.88e-05 | 12 | 41 | 2 | 20034106 | ||
| Pubmed | 9.68e-05 | 75 | 41 | 3 | 20637190 | ||
| Pubmed | 1.05e-04 | 13 | 41 | 2 | 12815621 | ||
| Pubmed | Abnormal development of the apical ectodermal ridge and polysyndactyly in Megf7-deficient mice. | 1.05e-04 | 13 | 41 | 2 | 16207730 | |
| Pubmed | Proteomic analysis reveals new cardiac-specific dystrophin-associated proteins. | 1.22e-04 | 14 | 41 | 2 | 22937058 | |
| Pubmed | 1.41e-04 | 15 | 41 | 2 | 18639653 | ||
| Pubmed | ADAMTS2 promotes radial migration by activating TGF-β signaling in the developing neocortex. | 1.41e-04 | 15 | 41 | 2 | 38871984 | |
| Pubmed | Sox17 is essential for the specification of cardiac mesoderm in embryonic stem cells. | 1.41e-04 | 15 | 41 | 2 | 17360443 | |
| Pubmed | 1.58e-04 | 231 | 41 | 4 | 21048031 | ||
| Pubmed | 1.61e-04 | 16 | 41 | 2 | 27732850 | ||
| Pubmed | Deletion of STK40 protein in mice causes respiratory failure and death at birth. | 2.05e-04 | 18 | 41 | 2 | 23293024 | |
| Pubmed | Switching axial progenitors from producing trunk to tail tissues in vertebrate embryos. | 2.29e-04 | 19 | 41 | 2 | 23763947 | |
| Pubmed | ATXN1 protein family and CIC regulate extracellular matrix remodeling and lung alveolarization. | 2.29e-04 | 19 | 41 | 2 | 22014525 | |
| Pubmed | 2.81e-04 | 21 | 41 | 2 | 33871356 | ||
| Pubmed | Congenital heart defect causing mutation in Nkx2.5 displays in vivo functional deficit. | 2.81e-04 | 21 | 41 | 2 | 28302382 | |
| Pubmed | DOT1L regulates dystrophin expression and is critical for cardiac function. | 2.81e-04 | 21 | 41 | 2 | 21289070 | |
| Interaction | MMP17 interactions | 2.77e-09 | 10 | 40 | 4 | int:MMP17 | |
| Interaction | MMP16 interactions | 3.99e-08 | 18 | 40 | 4 | int:MMP16 | |
| Interaction | MMP8 interactions | 1.63e-07 | 25 | 40 | 4 | int:MMP8 | |
| Interaction | MMP11 interactions | 1.57e-06 | 12 | 40 | 3 | int:MMP11 | |
| Interaction | MMP25 interactions | 2.04e-06 | 13 | 40 | 3 | int:MMP25 | |
| Interaction | MMP24 interactions | 6.87e-06 | 19 | 40 | 3 | int:MMP24 | |
| Interaction | MMP10 interactions | 2.83e-05 | 30 | 40 | 3 | int:MMP10 | |
| Interaction | MMP13 interactions | 3.13e-05 | 31 | 40 | 3 | int:MMP13 | |
| Interaction | SSPN interactions | 3.83e-05 | 5 | 40 | 2 | int:SSPN | |
| Interaction | MMP1 interactions | 5.37e-05 | 37 | 40 | 3 | int:MMP1 | |
| Interaction | WNT3A interactions | 1.25e-04 | 49 | 40 | 3 | int:WNT3A | |
| Interaction | MMP27 interactions | 2.09e-04 | 11 | 40 | 2 | int:MMP27 | |
| Cytoband | 12q13.3 | 9.65e-04 | 51 | 41 | 2 | 12q13.3 | |
| Cytoband | 19p13.2 | 1.14e-03 | 229 | 41 | 3 | 19p13.2 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr9q34 | 3.07e-03 | 325 | 41 | 3 | chr9q34 | |
| Cytoband | 9q34.3 | 4.08e-03 | 106 | 41 | 2 | 9q34.3 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr19p13 | 5.49e-03 | 797 | 41 | 4 | chr19p13 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr12q13 | 6.39e-03 | 423 | 41 | 3 | chr12q13 | |
| GeneFamily | Endogenous ligands|Matrix metallopeptidases | 2.00e-12 | 24 | 31 | 6 | 891 | |
| GeneFamily | Fibrinogen C domain containing | 1.02e-05 | 25 | 31 | 3 | 554 | |
| GeneFamily | Fibrinogen C domain containing|Angiopoietin like | 7.92e-05 | 8 | 31 | 2 | 905 | |
| GeneFamily | Endogenous ligands | 7.63e-03 | 237 | 31 | 3 | 542 | |
| Coexpression | NABA_MATRISOME | MMP25 ADAMTS10 COL5A3 FGF8 ANGPTL6 BRINP3 VTN MMP2 HCFC2 MMP11 MMP16 MMP17 MMP19 ANGPTL7 FCN2 WNT2 | 8.50e-13 | 1008 | 41 | 16 | MM17056 |
| Coexpression | NABA_MATRISOME | MMP25 ADAMTS10 COL5A3 FGF8 ANGPTL6 BRINP3 VTN MMP2 HCFC2 MMP11 MMP16 MMP17 MMP19 ANGPTL7 FCN2 WNT2 | 1.11e-12 | 1026 | 41 | 16 | M5889 |
| Coexpression | NABA_MATRISOME_ASSOCIATED | MMP25 ADAMTS10 FGF8 ANGPTL6 BRINP3 MMP2 HCFC2 MMP11 MMP16 MMP17 MMP19 ANGPTL7 FCN2 WNT2 | 3.04e-12 | 738 | 41 | 14 | MM17058 |
| Coexpression | NABA_MATRISOME_ASSOCIATED | MMP25 ADAMTS10 FGF8 ANGPTL6 BRINP3 MMP2 HCFC2 MMP11 MMP16 MMP17 MMP19 ANGPTL7 FCN2 WNT2 | 3.84e-12 | 751 | 41 | 14 | M5885 |
| Coexpression | NABA_ECM_REGULATORS | 8.05e-08 | 238 | 41 | 7 | M3468 | |
| Coexpression | NABA_ECM_REGULATORS | 9.02e-08 | 242 | 41 | 7 | MM17062 | |
| Coexpression | KATSANOU_ELAVL1_TARGETS_DN | 3.30e-06 | 147 | 41 | 5 | M2387 | |
| Coexpression | KATSANOU_ELAVL1_TARGETS_DN | 4.70e-06 | 158 | 41 | 5 | MM934 | |
| Coexpression | TRAVAGLINI_LUNG_ALVEOLAR_FIBROBLAST_CELL | 5.63e-06 | 164 | 41 | 5 | M41676 | |
| Coexpression | NABA_SECRETED_FACTORS | 1.35e-05 | 338 | 41 | 6 | MM17064 | |
| Coexpression | NABA_SECRETED_FACTORS | 1.47e-05 | 343 | 41 | 6 | M5883 | |
| Coexpression | HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION | 1.47e-05 | 200 | 41 | 5 | M5930 | |
| Coexpression | VERRECCHIA_DELAYED_RESPONSE_TO_TGFB1 | 2.66e-05 | 37 | 41 | 3 | M16643 | |
| Coexpression | CHIBA_RESPONSE_TO_TSA_UP | 6.62e-05 | 50 | 41 | 3 | M10372 | |
| Coexpression | GAO_LARGE_INTESTINE_ADULT_CJ_IMMUNE_CELLS | 1.26e-04 | 505 | 41 | 6 | M39167 | |
| Coexpression | PETRETTO_BLOOD_PRESSURE_UP | 1.56e-04 | 12 | 41 | 2 | M14298 | |
| Coexpression | MANNO_MIDBRAIN_NEUROTYPES_HOPC | 2.56e-04 | 366 | 41 | 5 | M39052 | |
| Coexpression | GSE22886_NAIVE_VS_IGG_IGA_MEMORY_BCELL_UP | 2.57e-04 | 198 | 41 | 4 | M4432 | |
| Coexpression | GSE12845_IGD_POS_VS_NEG_BLOOD_BCELL_UP | 2.62e-04 | 199 | 41 | 4 | M3182 | |
| Coexpression | GSE24726_WT_VS_E2_2_KO_PDC_DAY6_POST_DELETION_DN | 2.67e-04 | 200 | 41 | 4 | M8056 | |
| Coexpression | GSE21670_TGFB_VS_IL6_TREATED_CD4_TCELL_UP | 2.67e-04 | 200 | 41 | 4 | M7437 | |
| Coexpression | JI_CARCINOGENESIS_BY_KRAS_AND_STK11_DN | 3.20e-04 | 17 | 41 | 2 | M1767 | |
| Coexpression | JI_CARCINOGENESIS_BY_KRAS_AND_STK11_DN | 3.20e-04 | 17 | 41 | 2 | MM1225 | |
| Coexpression | GAUTAM_EYE_IRIS_CILIARY_BODY_SCHWANN_CELLS | 3.92e-04 | 91 | 41 | 3 | M43622 | |
| ToppCell | droplet-Heart-nan-3m-Mesenchymal|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.08e-08 | 190 | 41 | 6 | 96a92212ea3fb35fa3d0da495e504edc61c71c23 | |
| ToppCell | 5'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_2-Alveolar_fibroblasts|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 2.43e-08 | 195 | 41 | 6 | 4243190ad291d56694e2155954dbaa879c9d3844 | |
| ToppCell | 5'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_2-Alveolar_fibroblasts-Alveolar_fibroblasts_L.2.1.1.0|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 2.43e-08 | 195 | 41 | 6 | df409f94f4e83be89f7a608058ee07ce3ce3a149 | |
| ToppCell | Fetal_29-31_weeks-Mesenchymal-matrix_fibroblast_2_cell-D062|Fetal_29-31_weeks / Lineage, Cell type, age group and donor | 2.51e-08 | 196 | 41 | 6 | 525d6c8a277364e624e7cc586275f8a891436b57 | |
| ToppCell | 343B-Fibroblasts-Fibroblast-G|343B / Donor, Lineage, Cell class and subclass (all cells) | 2.74e-08 | 199 | 41 | 6 | f4b6c095cbe7a38b310adc49be4069e4d56e6a66 | |
| ToppCell | 343B-Fibroblasts-Fibroblast-G-|343B / Donor, Lineage, Cell class and subclass (all cells) | 2.74e-08 | 199 | 41 | 6 | 9c6d1c328bfbb6547f4c7bb2a784576a56bd72af | |
| ToppCell | P15-Mesenchymal-developing_mesenchymal_cell-mesenchymal_immature_unknown_1|P15 / developmental_time, Lineage, Cell group, Cell type, Cell type_cellcyc-phase | 5.47e-07 | 174 | 41 | 5 | 3c47d069bd836599a8d40eae485c23d4d3487517 | |
| ToppCell | 356C-Fibroblasts-Fibroblast-G-|356C / Donor, Lineage, Cell class and subclass (all cells) | 5.95e-07 | 177 | 41 | 5 | 7617270f49cd6b7ba66db72d20560cee985012b2 | |
| ToppCell | 356C-Fibroblasts-Fibroblast-G|356C / Donor, Lineage, Cell class and subclass (all cells) | 5.95e-07 | 177 | 41 | 5 | 8220cc2fc0ee8764a67a3be51d75248be2453040 | |
| ToppCell | -Donor_06|World / lung cells shred on cell class, cell subclass, sample id | 6.29e-07 | 179 | 41 | 5 | e4224b2e9c4ae7da62cf670adf811f4112c7d060 | |
| ToppCell | kidney_cells-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Fibroblast-kidney_interstitial_fibroblast|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 6.46e-07 | 180 | 41 | 5 | c2746092ef251e9d5910fe96461afdd0624a24c6 | |
| ToppCell | kidney_cells-Renal_AKI_(acute_kidney_injury)-Mesenchymal-Fibroblast-kidney_interstitial_fibroblast-Adaptive_/_Maladaptive_/_Repairing_Fibroblast|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group | 6.46e-07 | 180 | 41 | 5 | 32c6a3886428d82fb4355d987c6d2645f333447b | |
| ToppCell | 390C-Fibroblasts-Fibroblast-F|390C / Donor, Lineage, Cell class and subclass (all cells) | 7.40e-07 | 185 | 41 | 5 | 2c1f14f77faeee2acb388d997c5a27a7fef79be1 | |
| ToppCell | 390C-Fibroblasts-Fibroblast-F-|390C / Donor, Lineage, Cell class and subclass (all cells) | 7.40e-07 | 185 | 41 | 5 | 37db8e0b1f59274227f6fc2362167eb44bd080ef | |
| ToppCell | 5'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_2-Alveolar_fibroblasts-Alveolar_fibroblasts_L.2.1.1.1|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 7.60e-07 | 186 | 41 | 5 | 5473283fb95cee556b1f6934cf72169b676b5bcc | |
| ToppCell | facs-Brain_Non-Myeloid-Cerebellum-3m-Macroglial-oligodendrocyte_precursor_cell|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 8.01e-07 | 188 | 41 | 5 | a244fcd092d5bd544e503366b1439b0fbc1ee00e | |
| ToppCell | (2)_Fibroblasts-(20)_Fibro-1|World / Cell class and subclass of bone marrow stroma cells in homeostatis | 8.01e-07 | 188 | 41 | 5 | 409a7b69d02e87084ca955e3fe6c77230dee8861 | |
| ToppCell | facs-Brain_Non-Myeloid-Cerebellum-3m-Macroglial-Oligodendrocyte_progenitor_cell|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 8.01e-07 | 188 | 41 | 5 | c8530c9ff98666c64a94683261af4288cb790a7e | |
| ToppCell | LPS_only-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 8.22e-07 | 189 | 41 | 5 | 2a22b9fae70afb3dab8476f9c00e48a4df756410 | |
| ToppCell | droplet-Mammary_Gland-nan-3m-Mesenchymal|Mammary_Gland / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 8.44e-07 | 190 | 41 | 5 | bd0d68dc1b6f388190a6ba8a83b011619abe2bdd | |
| ToppCell | droplet-Mammary_Gland-nan-3m-Mesenchymal-stromal_cell|Mammary_Gland / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 8.44e-07 | 190 | 41 | 5 | e275de94468872e70cf305b3b450823d4c9c5e3f | |
| ToppCell | droplet-Mammary_Gland-nan-3m-Mesenchymal-stromal_cell|Mammary_Gland / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 8.44e-07 | 190 | 41 | 5 | ee2f4a55d2fd18b83e55399b5b5697a15a2d2e70 | |
| ToppCell | kidney_cells-Adult_normal_reference-Mesenchymal-Fibroblast-Degenerative_Fibroblast|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 8.89e-07 | 192 | 41 | 5 | 41a8326cd5bc19ad5041068501bab4c72399222e | |
| ToppCell | LPS-IL1RA+antiTNF-Stromal_mesenchymal|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 8.89e-07 | 192 | 41 | 5 | 3d0cb19f037f604253d7d728689aeaa94251e92b | |
| ToppCell | Children_(3_yrs)-Mesenchymal-matrix_fibroblast_2_cell-D046|Children_(3_yrs) / Lineage, Cell type, age group and donor | 8.89e-07 | 192 | 41 | 5 | e0f4e4470a71bfa81d9dcd8594e5f82aafc24f81 | |
| ToppCell | kidney_cells-Adult_normal_reference-Mesenchymal-Fibroblast-Degenerative_Fibroblast-Degenerative_Fibroblast_119|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 8.89e-07 | 192 | 41 | 5 | f88aba74d6e8c594c32fe2bc095b5da28b4b28e9 | |
| ToppCell | Mesenchymal-matrix_fibroblast_2_cell|World / Lineage, Cell type, age group and donor | 8.89e-07 | 192 | 41 | 5 | a769158c49d2b208c4224d85e7ae68c85cc372ed | |
| ToppCell | Children_(3_yrs)-Mesenchymal-matrix_fibroblast_2_cell|Children_(3_yrs) / Lineage, Cell type, age group and donor | 9.12e-07 | 193 | 41 | 5 | 9ab47b360bee1d4f1092c2269e58acebe9584021 | |
| ToppCell | 10x5'v1-week_12-13-Mesenchymal_fibro-stroma-arteriolar_fibroblast|week_12-13 / cell types per 3 fetal stages;per 3',per 5' | 9.12e-07 | 193 | 41 | 5 | 3d85c28f6ebdcb15e875ad01d52d6c138fbf8525 | |
| ToppCell | PCW_07-8.5-Mesenchymal-Mesenchymal_fibroblastic|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung | 9.35e-07 | 194 | 41 | 5 | 8c37bedb23285735ff3828db3889897fada8c95d | |
| ToppCell | LPS-antiTNF-Stromal_mesenchymal|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 9.35e-07 | 194 | 41 | 5 | 6e13549f697f7478b34fe71f7dd9d63c5d3db22e | |
| ToppCell | droplet-Heart-nan-3m-Mesenchymal-fibroblast|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 9.35e-07 | 194 | 41 | 5 | ce32e60bcea1b8baf496ce9050832bc8c77d8434 | |
| ToppCell | droplet-Heart-nan-3m-Mesenchymal-fibroblast_of_cardiac_tissue|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 9.35e-07 | 194 | 41 | 5 | a1dc157148885cc8d3685ac81a1f4e3562aeecc9 | |
| ToppCell | PCW_10-12-Mesenchymal-Mesenchymal_fibroblastic-mes_immature_COL13A1^pos_fibro1_(4)|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung | 9.35e-07 | 194 | 41 | 5 | 71d3c7448b1734de54187f902f65649f9283bd4c | |
| ToppCell | 3'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_2-Alveolar_fibroblasts|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 9.84e-07 | 196 | 41 | 5 | cecf82cd5e0a3835d655f5e7478578674a63ce25 | |
| ToppCell | 3'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_2|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 9.84e-07 | 196 | 41 | 5 | 9737a5f006d37b549f281e1863aca558e1e4dc99 | |
| ToppCell | Parenchymal-10x5prime-Stromal-Mesofibroblastic|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 1.01e-06 | 197 | 41 | 5 | 88a86286b9c3ea3b076d7464faec42d0392ee7f8 | |
| ToppCell | Parenchymal-10x5prime-Stromal-Mesofibroblastic-Mesothelia|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 1.01e-06 | 197 | 41 | 5 | 2773d2eb5f232a7e49da116efffcb6bf5eb90810 | |
| ToppCell | 3'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_2-Alveolar_fibroblasts-Alveolar_fibroblasts_L.2.1.1.0|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 1.01e-06 | 197 | 41 | 5 | 13896ec65ccda0b928c91d41112dc01b480036b7 | |
| ToppCell | tumor_Lung-Fibroblasts-Myofibroblasts|tumor_Lung / Location, Cell class and cell subclass | 1.03e-06 | 198 | 41 | 5 | 31f9181dab689aabe9c6182c2ef7de65ba3f0ff6 | |
| ToppCell | cellseq-Mesenchymal-Fibroblastic-Fibroblastic_2-AF1|cellseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 1.03e-06 | 198 | 41 | 5 | f1374f7a50244d59c766ac41f44c08c9117407d2 | |
| ToppCell | Biopsy_Control_(H.)-Mesenchymal-Myofibroblasts|Biopsy_Control_(H.) / Sample group, Lineage and Cell type | 1.06e-06 | 199 | 41 | 5 | 7a227c239afdaebcac84644d9b2653a5f1a4be71 | |
| ToppCell | cellseq-Mesenchymal-Fibroblastic-Fibroblastic_2|cellseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 1.06e-06 | 199 | 41 | 5 | 66a79732caf2f04c09b4d9832377aa01ca477677 | |
| ToppCell | Fibroblasts|World / lung cells shred on cell class, cell subclass, sample id | 1.06e-06 | 199 | 41 | 5 | e2b6752fcabd5249a166486ae6796f2c97c1fcaf | |
| ToppCell | (5)_Fibroblast-G|World / Lung cell shreds - cell class (v4) and cell subclass (v4) | 1.06e-06 | 199 | 41 | 5 | b4a737575be9f8c65771832dd8cd25328d5dae0d | |
| ToppCell | 10x3'2.3-week_17-19-Mesenchymal_fibro-stroma|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 1.09e-06 | 200 | 41 | 5 | 747c61d4e0b746278ae1f45ca4cd556c6961c76a | |
| ToppCell | distal-mesenchymal-Myofibroblast-3|distal / Location, Lineage, Cell class (ontology) and Donor from 10X sequencing (macrophage renamed) | 1.09e-06 | 200 | 41 | 5 | 069c8949b33ecfdb6da32992002d4060ff6082bc | |
| ToppCell | 10x5'v1-week_14-16-Mesenchymal_osteo-stroma-early_osteoblast|week_14-16 / cell types per 3 fetal stages;per 3',per 5' | 1.09e-06 | 200 | 41 | 5 | 16a7c398626b6e82b394eb3ef013bda3a788659d | |
| ToppCell | Parenchymal-10x5prime-Stromal-Fibroblastic-Fibro_alveolar|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 1.09e-06 | 200 | 41 | 5 | 8c62f05c6042f24287a73fbdf80ff4a56f7ff403 | |
| ToppCell | 10x3'2.3-week_17-19-Mesenchymal_fibro|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 1.09e-06 | 200 | 41 | 5 | de1d193f773f4e2927baa6fc38d29754b015c6e6 | |
| ToppCell | Frontal_cortex-Endothelial-MURAL|Frontal_cortex / BrainAtlas - Mouse McCarroll V32 | 1.12e-05 | 151 | 41 | 4 | 7570372a315bc312ff57bb5f483375c401ae8787 | |
| ToppCell | Frontal_cortex-Endothelial-MURAL-M1(Rgs5Acta2)|Frontal_cortex / BrainAtlas - Mouse McCarroll V32 | 1.12e-05 | 151 | 41 | 4 | 527059e47e381b2f6d63c1abb39bc0795ee3829d | |
| ToppCell | 5'-Airway_Nasal-Mesenchymal-Fibroblastic-fibroblastic_type_1-Adventitial_fibroblasts-|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 1.67e-05 | 167 | 41 | 4 | 805129f887078340b260aa136b0ba19f2bd6ea03 | |
| ToppCell | 5'-Airway_Nasal-Mesenchymal-Fibroblastic-fibroblastic_type_1|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 1.67e-05 | 167 | 41 | 4 | 31cf8bf2eb523f6e7e319620648ff37fc09e2601 | |
| ToppCell | 5'-Airway_Nasal-Mesenchymal-Fibroblastic-fibroblastic_type_1-Adventitial_fibroblasts|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 1.67e-05 | 167 | 41 | 4 | 3acb18428d1d33ad430c2fd031b1a91baee3c01d | |
| ToppCell | -Donor_05|World / lung cells shred on cell class, cell subclass, sample id | 1.75e-05 | 169 | 41 | 4 | 8ebe9a88111c53a09c25a7b6a164a0a17880458d | |
| ToppCell | Control-Stromal_mesenchymal-Lung_smooth_muscle-Pericyte_2|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.79e-05 | 170 | 41 | 4 | 5570c0e825bca77613bf0ebde620cf744fa1cb84 | |
| ToppCell | facs-Heart-RV-18m-Mesenchymal|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.79e-05 | 170 | 41 | 4 | d7c9a604311974ff87ece43a0f8725a234d262f7 | |
| ToppCell | Pericytes-Donor_02|World / lung cells shred on cell class, cell subclass, sample id | 1.83e-05 | 171 | 41 | 4 | bbc8d9fc83d37c9250345b1e76776610799de9ae | |
| ToppCell | nucseq-Mesenchymal-Fibroblastic-Fibroblastic_2-ASMC|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 1.91e-05 | 173 | 41 | 4 | cb6389536195443633adb06e5f1b7483530773d1 | |
| ToppCell | kidney_cells-Hypertensive_with+without-CKD-Mesenchymal-Fibroblast-kidney_interstitial_fibroblast-Adaptive_/_Maladaptive_/_Repairing_Fibroblast|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 1.96e-05 | 174 | 41 | 4 | 9c916af5eebd932f67dc9117e1d26ff194a2ff2c | |
| ToppCell | kidney_cells-Hypertensive_with+without-CKD-Mesenchymal-Fibroblast-kidney_interstitial_fibroblast|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 1.96e-05 | 174 | 41 | 4 | bc71521f44a5fe013af42b06b5d1bd2446ecf3b5 | |
| ToppCell | facs-Marrow-B-cells-24m|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.00e-05 | 175 | 41 | 4 | 887e75fc90e59a6394d62f3c048a9cfdf6707725 | |
| ToppCell | facs-Heart-RV-18m-Mesenchymal-fibroblast_of_cardiac_tissue|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.05e-05 | 176 | 41 | 4 | c0a084f7a8645262d61971f094689e02bf15b113 | |
| ToppCell | facs-Marrow-B-cells-24m-Lymphocytic|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.05e-05 | 176 | 41 | 4 | c6484334187f64cd00cd35e77d8ae436556b4260 | |
| ToppCell | facs-Heart-RV-18m-Mesenchymal-fibroblast_of_cardiac_tissue|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.05e-05 | 176 | 41 | 4 | cccf9201f6e2da7524b911a5961d3b227edab222 | |
| ToppCell | 390C-Fibroblasts-Fibroblast-B_(Myofibroblast)|390C / Donor, Lineage, Cell class and subclass (all cells) | 2.05e-05 | 176 | 41 | 4 | 852d3da0907fe87c0ef23d75a63ce07619cf0c54 | |
| ToppCell | 390C-Fibroblasts-Fibroblast-B_(Myofibroblast)-|390C / Donor, Lineage, Cell class and subclass (all cells) | 2.05e-05 | 176 | 41 | 4 | d2df1e435996c51213e88270af9f928e9e09a6f5 | |
| ToppCell | facs-Lung-EPCAM-3m-Mesenchymal-adventitial_cell|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.14e-05 | 178 | 41 | 4 | 27497dbfcf9bb4dd0bf7caa0bd78c7e85f5c18ee | |
| ToppCell | TCGA-Ovary-Primary_Tumor-Ovarian_Carcinoma-Serous_Cystadenocarcinoma-6|TCGA-Ovary / Sample_Type by Project: Shred V9 | 2.14e-05 | 178 | 41 | 4 | 142879e9393e721f9b05a6bb46995c9d6d713c95 | |
| ToppCell | facs-Lung-EPCAM-3m-Mesenchymal-Adventitial_Fibroblast|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.14e-05 | 178 | 41 | 4 | d348a9550db940d204706529759dc51e30506b5f | |
| ToppCell | renal_cortex_nuclei-Hypertensive_with+without-CKD-Mesenchymal-Fibroblast-Degenerative_Fibroblast-Degenerative_Fibroblast_119|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 2.19e-05 | 179 | 41 | 4 | 68ccfe66474d049a926afc21bffa231446becc69 | |
| ToppCell | -Donor_02|World / lung cells shred on cell class, cell subclass, sample id | 2.19e-05 | 179 | 41 | 4 | 10fadbaa1b6d21cbf9f354d717cc4c225619f4fd | |
| ToppCell | 5'-Airway_Nasal-Mesenchymal-Fibroblastic|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 2.24e-05 | 180 | 41 | 4 | 935c091bbcd6d10b81dc4731779e5bd98205c99f | |
| ToppCell | Control-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.24e-05 | 180 | 41 | 4 | 08ae0f5d95c45feba68ad99788f7af7ff4c979af | |
| ToppCell | 5'-Airway_Nasal-Mesenchymal|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 2.24e-05 | 180 | 41 | 4 | 3dd384b7f3d9582b8fec9fe05100e466e6218b76 | |
| ToppCell | Children_(3_yrs)-Mesenchymal-matrix_fibroblast_1_cell-D046|Children_(3_yrs) / Lineage, Cell type, age group and donor | 2.28e-05 | 181 | 41 | 4 | 9ede19228ba5c0668a9c06c915510b95585216ef | |
| ToppCell | 5'-Airway_Nasal-Mesenchymal-Fibroblastic-fibroblastic_type_2-Peribronchial_fibroblasts-Peribronchial_fibroblasts_L.2.1.3.1|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 2.38e-05 | 183 | 41 | 4 | 6d98973098c6d20c5305bce6a83a549a7d8dbfba | |
| ToppCell | 5'-Airway_Nasal-Mesenchymal-Fibroblastic-fibroblastic_type_2-Peribronchial_fibroblasts|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 2.38e-05 | 183 | 41 | 4 | cc7f5a17b40e8d901885174922e5fa8877643071 | |
| ToppCell | 5'-Airway_Nasal-Mesenchymal-Fibroblastic-fibroblastic_type_2|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 2.38e-05 | 183 | 41 | 4 | 803376f5260de83c48d4f7301278d078a32b3e6e | |
| ToppCell | droplet-Mammary_Gland-nan-18m-Mesenchymal-nan|Mammary_Gland / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.44e-05 | 184 | 41 | 4 | fe4d3def3da4ffdea5ae6bb059f5397efd58fef3 | |
| ToppCell | TCGA-Bladder-Primary_Tumor-Urothelial_Carcinoma-Non-Papillary_Muscle_Invasive_Urothelial_Carcinoma-4|TCGA-Bladder / Sample_Type by Project: Shred V9 | 2.49e-05 | 185 | 41 | 4 | e1f3f0e974eb3fe1c05018beb9e124c7fb0cbe50 | |
| ToppCell | droplet-Kidney-KIDNEY-1m-Mesenchymal-podocyte|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.49e-05 | 185 | 41 | 4 | ca69499ba8c39b7ed6717d05685d6f70066a77bd | |
| ToppCell | 5'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_2-Peribronchial_fibroblasts-Peribronchial_fibroblasts_L.2.1.3.1|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 2.49e-05 | 185 | 41 | 4 | 87c416d14ca6255bee39b16e7571553e36ee3069 | |
| ToppCell | 5'-Adult-Distal_Rectal-Mesenchymal-fibroblastic-Stromal_1_(CCL11+)|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 2.54e-05 | 186 | 41 | 4 | f07e0c0d9c80ac9d8d679950e7d0c812becb85a3 | |
| ToppCell | PCW_05-06-Mesenchymal-Mesenchymal_fibroblastic-mes_immature_COL13A1^pos_fibro2_(5)|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung | 2.54e-05 | 186 | 41 | 4 | 7def03dd856b765bd3f493288641981c4f7fd26e | |
| ToppCell | Control-Fibroblasts-Other_FB|Control / group, cell type (main and fine annotations) | 2.59e-05 | 187 | 41 | 4 | bd3739c4a52aa1ba5deffd778e113a9800f7e158 | |
| ToppCell | facs-Bladder-nan-24m-Epithelial-bladder_cell|Bladder / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.59e-05 | 187 | 41 | 4 | 2c145e9d11424939dd99012a8cedf5d998b966e9 | |
| ToppCell | kidney_cells-Adult_normal_reference-Mesenchymal-Fibroblast-kidney_interstitial_fibroblast-Adaptive_/_Maladaptive_/_Repairing_Fibroblast|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 2.65e-05 | 188 | 41 | 4 | c32d023a69b6da79687ff8fa7485e7499db57046 | |
| ToppCell | kidney_cells-Adult_normal_reference-Mesenchymal-Fibroblast-kidney_interstitial_fibroblast|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group | 2.65e-05 | 188 | 41 | 4 | 1cd5a4d744bd3777246958ea5eb94388a5cbad81 | |
| ToppCell | facs-Brain_Non-Myeloid-Striatum-3m-Macroglial-Oligodendrocyte_progenitor_cell|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.65e-05 | 188 | 41 | 4 | 053c251d3ddbeb866f34565aefca4535517b4387 | |
| ToppCell | facs-Brain_Non-Myeloid-Striatum-3m-Macroglial-oligodendrocyte_precursor_cell|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.65e-05 | 188 | 41 | 4 | 7471c194276161422326647f09022e94f3d1640c | |
| ToppCell | droplet-Kidney-KIDNEY-30m-Mesenchymal-nan|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.71e-05 | 189 | 41 | 4 | 544d95df910f1b276995624509a7e41b219baca0 | |
| ToppCell | droplet-Heart-4Chambers-21m-Mesenchymal|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.71e-05 | 189 | 41 | 4 | 2a5fda73d38bdc23cf47e5335ffd4e086e990245 | |
| ToppCell | droplet-Mammary_Gland-nan-21m-Mesenchymal-stromal_cell|Mammary_Gland / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.71e-05 | 189 | 41 | 4 | bc54ffd7bd1627a36747a80ce5139e4a69928400 | |
| ToppCell | droplet-Limb_Muscle-MUSCLE-30m-Macroglial-Schwann_cell|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.76e-05 | 190 | 41 | 4 | ff3dec5b45c6ea9b5319fb51a0198c6773b7be26 | |
| ToppCell | droplet-Mammary_Gland-nan-21m-Mesenchymal-stromal_cell|Mammary_Gland / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.76e-05 | 190 | 41 | 4 | f3ca94a31a35eed5fecf3c4b8c957e1bc4150158 | |
| ToppCell | facs-Brain_Non-Myeloid-Cortex-3m-Macroglial-oligodendrocyte_precursor_cell|Brain_Non-Myeloid / Brain_Non-Myeloid_Brain_Myeloid - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.76e-05 | 190 | 41 | 4 | 9b825b2586c7b173ff27fcf2abc5860faf50984a | |
| ToppCell | droplet-Mammary_Gland-nan-21m-Mesenchymal|Mammary_Gland / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.76e-05 | 190 | 41 | 4 | c2cd1eb674162ee40502c3380b7245c85079c7ce | |
| ToppCell | LPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Diff_MatrixFB|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.76e-05 | 190 | 41 | 4 | 841cd55861b43578d704418b9bc0af2e8b88323a | |
| Drug | AC1L9M3B | 1.21e-11 | 61 | 40 | 7 | CID000448562 | |
| Drug | diacerein | 1.53e-11 | 63 | 40 | 7 | CID000026248 | |
| Drug | malolactomycin D | 1.74e-11 | 32 | 40 | 6 | CID006449115 | |
| Drug | DA-125 | 8.27e-10 | 26 | 40 | 5 | CID000114758 | |
| Drug | mercuric acetate | 1.78e-09 | 30 | 40 | 5 | CID000015337 | |
| Drug | AC1L1GXT | 3.37e-09 | 74 | 40 | 6 | CID000003890 | |
| Drug | peroxynitrite | 1.35e-08 | 373 | 40 | 9 | CID000104806 | |
| Drug | titanium | 1.73e-08 | 170 | 40 | 7 | CID000023963 | |
| Drug | AC1L1DD6 | 2.47e-08 | 179 | 40 | 7 | CID000002299 | |
| Drug | 4-aminophenyl | 7.77e-08 | 62 | 40 | 5 | CID000181201 | |
| Drug | pirfenidone | 1.44e-07 | 138 | 40 | 6 | CID000040632 | |
| Drug | nitric oxide | MMP25 MMP2 FCER2 MMP11 MMP16 MMP17 MMP19 ATP2A1 FCN2 SGCG WNT2 RYR2 | 1.89e-07 | 1075 | 40 | 12 | CID000145068 |
| Drug | A0395 | 2.04e-07 | 75 | 40 | 5 | CID009906466 | |
| Drug | AC1NSU5S | 2.04e-07 | 75 | 40 | 5 | CID005316299 | |
| Drug | enantio-PAF-C16 | 2.05e-07 | 244 | 40 | 7 | CID000002499 | |
| Drug | isoflavone | 2.86e-07 | 155 | 40 | 6 | CID000072304 | |
| Drug | carvedilol | 3.58e-07 | 161 | 40 | 6 | CID000002585 | |
| Drug | aldosterone | 3.76e-07 | 397 | 40 | 8 | CID000005839 | |
| Drug | latanoprost acid | 7.13e-07 | 40 | 40 | 4 | CID006441636 | |
| Drug | acetate | 7.51e-07 | 599 | 40 | 9 | CID000000175 | |
| Drug | quercetin | 1.61e-06 | 482 | 40 | 8 | CID005280343 | |
| Drug | oxidized glutathione | 2.66e-06 | 227 | 40 | 6 | CID000000975 | |
| Drug | AC1L1HMM | 2.68e-06 | 516 | 40 | 8 | CID000004196 | |
| Drug | losartan | 3.82e-06 | 378 | 40 | 7 | CID000003961 | |
| Drug | quinacrine | 3.94e-06 | 243 | 40 | 6 | CID000000237 | |
| Drug | MMI270 | 4.02e-06 | 18 | 40 | 3 | CID000446504 | |
| Drug | 2,2',3,5',6-pentachlorobiphenyl | 5.61e-06 | 20 | 40 | 3 | ctd:C032904 | |
| Drug | noradrealine | 5.94e-06 | 575 | 40 | 8 | CID000000951 | |
| Drug | 1,10-phenanthroline | 6.75e-06 | 267 | 40 | 6 | CID000001318 | |
| Drug | dioxane | 8.50e-06 | 278 | 40 | 6 | CID000031275 | |
| Drug | gluconate | 1.02e-05 | 287 | 40 | 6 | CID000000604 | |
| Drug | Pro-leu-gly | 1.27e-05 | 26 | 40 | 3 | CID000169533 | |
| Drug | Iopromide [73334-07-3]; Up 200; 5uM; MCF7; HT_HG-U133A | 2.37e-05 | 197 | 40 | 5 | 6842_UP | |
| Drug | PF-01378883-00 [351320-41-7]; Down 200; 10uM; MCF7; HT_HG-U133A | 2.43e-05 | 198 | 40 | 5 | 6363_DN | |
| Drug | Tranexamic acid [1197-18-8]; Up 200; 25.4uM; MCF7; HT_HG-U133A | 2.43e-05 | 198 | 40 | 5 | 6238_UP | |
| Drug | valerate | 3.07e-05 | 102 | 40 | 4 | CID000007991 | |
| Drug | raloxifene | 3.17e-05 | 351 | 40 | 6 | CID000005035 | |
| Drug | glutathione reduced | 3.58e-05 | 534 | 40 | 7 | CID000000745 | |
| Drug | mag-fura-2 | 3.74e-05 | 37 | 40 | 3 | CID000123839 | |
| Drug | NSC236997 | 3.79e-05 | 539 | 40 | 7 | CID000005300 | |
| Drug | benzoxazolinate | 4.49e-05 | 6 | 40 | 2 | CID005281925 | |
| Drug | Ser-Asp-Gly-Arg-Gly | 4.49e-05 | 6 | 40 | 2 | CID004640574 | |
| Drug | dibutyryl cyclic 3',5'-AMP | 4.89e-05 | 561 | 40 | 7 | CID000002460 | |
| Drug | pseudococaine | 5.40e-05 | 570 | 40 | 7 | CID000002826 | |
| Drug | 17alpha-estradiol | 6.37e-05 | 1303 | 40 | 10 | CID000000450 | |
| Drug | polyethylenimine | 7.45e-05 | 128 | 40 | 4 | CID000009033 | |
| Drug | AC1Q5TCI | 8.37e-05 | 8 | 40 | 2 | CID000000116 | |
| Drug | Marimastat | 8.37e-05 | 8 | 40 | 2 | DB00786 | |
| Drug | CGS 27023A | 1.08e-04 | 9 | 40 | 2 | ctd:C097658 | |
| Drug | AC1L1B55 | 1.31e-04 | 454 | 40 | 6 | CID000001287 | |
| Drug | bacoside A | 1.34e-04 | 10 | 40 | 2 | ctd:C500175 | |
| Drug | Thalidomide | 1.76e-04 | 479 | 40 | 6 | ctd:D013792 | |
| Drug | tetrahydroneopterin | 2.32e-04 | 13 | 40 | 2 | CID000161510 | |
| Drug | Phe-glu | 2.32e-04 | 13 | 40 | 2 | CID000151134 | |
| Drug | DB07883 | 3.11e-04 | 75 | 40 | 3 | CID000446476 | |
| Drug | Metoprolol | 3.36e-04 | 77 | 40 | 3 | ctd:D008790 | |
| Drug | AC1MQZ6I | 3.39e-04 | 190 | 40 | 4 | CID003509873 | |
| Drug | pentosan polysulfate | 3.62e-04 | 79 | 40 | 3 | CID000037720 | |
| Drug | (-)-Isoproterenol hydrochloride [5984-95-2]; Up 200; 16.2uM; MCF7; HT_HG-U133A | 3.67e-04 | 194 | 40 | 4 | 6833_UP | |
| Drug | Xylazine [7361-61-7]; Up 200; 18.2uM; HL60; HT_HG-U133A | 3.75e-04 | 195 | 40 | 4 | 2132_UP | |
| Drug | Nefopam hydrochloride [23327-57-3]; Up 200; 13.8uM; MCF7; HT_HG-U133A | 3.82e-04 | 196 | 40 | 4 | 4752_UP | |
| Drug | PHA-00851261E [724719-49-7]; Down 200; 1uM; PC3; HT_HG-U133A | 3.82e-04 | 196 | 40 | 4 | 3776_DN | |
| Drug | Dehydroisoandosterone 3-acetate [853-23-6]; Down 200; 12.2uM; PC3; HT_HG-U133A | 3.82e-04 | 196 | 40 | 4 | 6673_DN | |
| Drug | Kanamycin A sulfate [25389-94-0]; Up 200; 6.8uM; PC3; HT_HG-U133A | 3.89e-04 | 197 | 40 | 4 | 4625_UP | |
| Drug | Evoxine [522-11-2]; Up 200; 11.6uM; HL60; HT_HG-U133A | 3.89e-04 | 197 | 40 | 4 | 2186_UP | |
| Drug | Tiratricol, 3,3',5-triiodothyroacetic acid [51-24-1]; Down 200; 6.4uM; MCF7; HT_HG-U133A | 3.89e-04 | 197 | 40 | 4 | 2259_DN | |
| Drug | (+) -Levobunolol hydrochloride [47141-41-3]; Up 200; 12.2uM; MCF7; HT_HG-U133A | 3.89e-04 | 197 | 40 | 4 | 3355_UP | |
| Drug | magnesium | 3.95e-04 | 1325 | 40 | 9 | CID000000888 | |
| Drug | Laudanosine (R,S) [1699-51-0]; Up 200; 11.2uM; MCF7; HT_HG-U133A | 3.97e-04 | 198 | 40 | 4 | 2890_UP | |
| Drug | AG-013608 [351320-38-2]; Down 200; 10uM; MCF7; HT_HG-U133A | 3.97e-04 | 198 | 40 | 4 | 5904_DN | |
| Drug | U-62066 [87151-85-7]; Up 200; 1uM; PC3; HT_HG-U133A | 3.97e-04 | 198 | 40 | 4 | 4553_UP | |
| Drug | Acacetin [480-44-4]; Up 200; 14uM; MCF7; HT_HG-U133A | 3.97e-04 | 198 | 40 | 4 | 6044_UP | |
| Drug | Tinidazole [19387-91-8]; Down 200; 16.2uM; MCF7; HT_HG-U133A | 3.97e-04 | 198 | 40 | 4 | 4370_DN | |
| Drug | Budesonide [51333-22-3]; Up 200; 9.2uM; MCF7; HT_HG-U133A | 3.97e-04 | 198 | 40 | 4 | 5431_UP | |
| Drug | Remoxipride Hydrochloride [73220-03-8]; Up 200; 9.8uM; MCF7; HT_HG-U133A | 3.97e-04 | 198 | 40 | 4 | 5443_UP | |
| Drug | Clemizole hydrochloride [1163-36-6]; Up 200; 11uM; MCF7; HT_HG-U133A | 3.97e-04 | 198 | 40 | 4 | 4695_UP | |
| Drug | Azaguanine-8 [134-58-7]; Up 200; 26.2uM; MCF7; HT_HG-U133A | 3.97e-04 | 198 | 40 | 4 | 1670_UP | |
| Drug | Mepenzolate bromide [76-90-4]; Up 200; 9.6uM; PC3; HT_HG-U133A | 3.97e-04 | 198 | 40 | 4 | 3748_UP | |
| Drug | Meticrane [1084-65-7]; Up 200; 14.6uM; MCF7; HT_HG-U133A | 3.97e-04 | 198 | 40 | 4 | 1671_UP | |
| Drug | rofecoxib; Up 200; 10uM; MCF7; HG-U133A | 3.97e-04 | 198 | 40 | 4 | 256_UP | |
| Drug | Glutethimide, para-amino [125-84-8]; Up 200; 17.2uM; MCF7; HT_HG-U133A | 3.97e-04 | 198 | 40 | 4 | 7421_UP | |
| Drug | thiirane | 4.03e-04 | 17 | 40 | 2 | CID000009865 | |
| Drug | biopterin | 4.04e-04 | 82 | 40 | 3 | CID000002380 | |
| Drug | Etofylline [519-37-9]; Up 200; 17.8uM; PC3; HT_HG-U133A | 4.05e-04 | 199 | 40 | 4 | 5048_UP | |
| Drug | CGX 0596987; Down 200; 20uM; MCF7; HT_HG-U133A | 4.05e-04 | 199 | 40 | 4 | 6364_DN | |
| Drug | Homosalate [118-56-9]; Down 200; 15.2uM; MCF7; HT_HG-U133A | 4.05e-04 | 199 | 40 | 4 | 3879_DN | |
| Drug | 0317956-0000 [391210-11-0]; Up 200; 10uM; PC3; HT_HG-U133A | 4.05e-04 | 199 | 40 | 4 | 3774_UP | |
| Drug | Fluvastatin sodium salt [93957-55-2]; Up 200; 9.2uM; HL60; HT_HG-U133A | 4.05e-04 | 199 | 40 | 4 | 3032_UP | |
| Drug | valdecoxib; Up 200; 10uM; MCF7; HT_HG-U133A | 4.12e-04 | 200 | 40 | 4 | 6403_UP | |
| Drug | Deferoxamine mesylate [138-14-7]; Up 200; 6uM; MCF7; HT_HG-U133A | 4.12e-04 | 200 | 40 | 4 | 3936_UP | |
| Drug | Spectinomycin dihydrochloride [21736-83-4]; Up 200; 9.8uM; HL60; HT_HG-U133A | 4.12e-04 | 200 | 40 | 4 | 2987_UP | |
| Drug | t5mvntj c2mvmr[wln] | 5.05e-04 | 19 | 40 | 2 | CID000115176 | |
| Drug | AC1L380G | 5.05e-04 | 19 | 40 | 2 | CID000084698 | |
| Disease | dilated cardiomyopathy 1L (implicated_via_orthology) | 5.10e-06 | 3 | 39 | 2 | DOID:0110436 (implicated_via_orthology) | |
| Disease | dipeptidyl peptidase 2 measurement | 3.56e-05 | 7 | 39 | 2 | EFO_0020326 | |
| Disease | cardiomyopathy (implicated_via_orthology) | 1.15e-04 | 71 | 39 | 3 | DOID:0050700 (implicated_via_orthology) | |
| Disease | mannan-binding lectin serine protease 1 measurement | 1.77e-04 | 15 | 39 | 2 | EFO_0008223 | |
| Disease | muscular dystrophy (implicated_via_orthology) | 3.52e-04 | 21 | 39 | 2 | DOID:9884 (implicated_via_orthology) | |
| Disease | Limb-girdle muscular dystrophy | 5.42e-04 | 26 | 39 | 2 | cv:C0686353 | |
| Disease | Muscular Dystrophies, Limb-Girdle | 8.23e-04 | 32 | 39 | 2 | C0686353 | |
| Disease | metastasis measurement, disease progression measurement | 9.30e-04 | 34 | 39 | 2 | EFO_0007675, EFO_0008336 | |
| Disease | heart disease (implicated_via_orthology) | 1.16e-03 | 38 | 39 | 2 | DOID:114 (implicated_via_orthology) |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| FSTRYKIYREFGRWK | 71 | Q76B58 | |
| KREFGFYSKSQYRTW | 1146 | Q4VNC0 | |
| YGYFAGLCRRLQKFW | 16 | H3BNL8 | |
| GVFNEYRTIWFKSYR | 51 | Q9NZJ6 | |
| GSWFRGAIYYFKIAV | 286 | O14983 | |
| FRGKFYKWKTYRGGG | 621 | Q9H324 | |
| RAKKIFGWGDFYFRV | 101 | O95158 | |
| YIFAGDKFWRYNEVK | 581 | P08253 | |
| KCVVRYRGKTYSGYW | 86 | Q5T6V5 | |
| LVSFYRDWKQYKQGF | 181 | O43827 | |
| GKTYLVRGRQYWRYD | 426 | Q9NPA2 | |
| RLYFWSGRDGYKKAL | 326 | Q9Y5Z7 | |
| SYLFGFYKRFESWRV | 76 | Q13021 | |
| VFWYKRRVQGAKGFQ | 4441 | Q07954 | |
| RGKTYAFKGDYVWTV | 301 | Q99542 | |
| QDGRVYFFKGKVYWR | 436 | Q99542 | |
| KWINFQRKCYYFGKG | 166 | P06734 | |
| YFTKRGYAWDGKSVV | 336 | P14867 | |
| YIKGYQRRWFVLSNG | 101 | P22059 | |
| ETVYGLKKFRWYRFQ | 1541 | Q9UMZ3 | |
| NAKYEGWYMAFTRKG | 161 | P55075 | |
| FSYFWIKGDFGIYRV | 476 | Q96PB1 | |
| YRDWATYKQGFGSRL | 156 | Q15485 | |
| VYWAEFRGGAYSLRK | 446 | Q8NI99 | |
| FYKYSRAVRRFDWGA | 236 | Q6BAA4 | |
| FQQRGKKAFEWYGTY | 21 | Q8N6R0 | |
| EKTYAVKAGRWYFEF | 1091 | Q92736 | |
| GGWYSTFRRGKKFSY | 1606 | P25940 | |
| SIIGWFVRSFKYFYG | 61 | O15120 | |
| EKNKIYFFRGRDYWR | 396 | P24347 | |
| RYFGGMVWYFVNNKK | 266 | P82650 | |
| KDWVFINYTYKRFEG | 436 | Q15208 | |
| MRVRKGFEDWYSGYF | 291 | Q7RTX9 | |
| QIRGEAFFFKGKYFW | 341 | Q9ULZ9 | |
| AFFFKGKYFWRLTRD | 346 | Q9ULZ9 | |
| RYFFRMEKGSIKWNY | 116 | Q9Y336 | |
| QYVYKIGIYGWRKRC | 21 | Q13326 | |
| DFRKTGDYLWRKYNG | 226 | P09544 | |
| EDVGKTYFFKGDRYW | 446 | P51512 | |
| VYKVGIYGWRKRCLY | 21 | Q92629 | |
| FSIEKRFAYWSGYVK | 1066 | Q5SRE5 | |
| YVAARFYKSFGGEKW | 416 | Q99805 | |
| QGKTYLFKGSQYWRF | 216 | P04004 | |
| SGRERVYFFKGKQYW | 266 | P04004 | |
| FPQKFGRWTDYAKRY | 206 | Q5FWF4 |